Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS)

L. Perreault, Q. Pan, V. R. Aroda, E. Barrett-Connor, D. Dabelea, S. Dagogo-Jack, R. F. Hamman, S. E. Kahn, Kieren Mather, W. C. Knowler

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: Approximately half of the participants in the Diabetes Prevention Outcomes Study (DPPOS) had diabetes after 15 years of follow-up, whereas nearly all the others remained with pre-diabetes. We examined whether formerly unexplored factors in the DPPOS coexisted with known risk factors that posed additional risk for, or protection from, diabetes as well as microvascular disease. Methods: Cox proportional hazard models were used to examine predictors of diabetes. Sequential modelling procedures considered known and formerly unexplored factors. We also constructed models to determine whether the same unexplored factors that associated with progression to diabetes also predicted the prevalence of microvascular disease. Hazard ratios (HR) are per standard deviation change in the variable. Results: In models adjusted for demographics and known diabetes risk factors, two formerly unknown factors were associated with risk for both diabetes and microvascular disease: number of medications taken (HR = 1.07, 95% confidence intervals (95% CI) 1.03 to 1.12 for diabetes; odds ratio (OR) = 1.10, 95% CI 1.04 to 1.16 for microvascular disease) and variability in HbA1c (HR = 1.02, 95% CI 1.01 to 1.03 for diabetes; OR = 1.06, 95% CI 1.04 to 1.09 for microvascular disease per sd). Total comorbidities increased risk for diabetes (HR = 1.10, 95% CI 1.04 to 1.16), whereas higher systolic (OR = 1.22, 95% CI 1.13 to 1.31) and diastolic (OR = 1.14, 95% CI 1.05 to 1.22) blood pressure, as well as the use of anti-hypertensives (OR = 1.41, 95% CI 1.23 to 1.62), increased risk of microvascular disease. Conclusions: Several formerly unexplored factors in the DPPOS predicted additional risk for diabetes and/or microvascular disease - particularly hypertension and the use of anti-hypertensive medications - helping to explain some of the residual disease risk in participants of the DPPOS.

Original languageEnglish (US)
JournalDiabetic Medicine
DOIs
StateAccepted/In press - 2017

Fingerprint

Outcome Assessment (Health Care)
Confidence Intervals
Odds Ratio
Antihypertensive Agents
Proportional Hazards Models
Comorbidity
Demography
Blood Pressure
Hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Perreault, L., Pan, Q., Aroda, V. R., Barrett-Connor, E., Dabelea, D., Dagogo-Jack, S., ... Knowler, W. C. (Accepted/In press). Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetic Medicine. https://doi.org/10.1111/dme.13453

Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). / Perreault, L.; Pan, Q.; Aroda, V. R.; Barrett-Connor, E.; Dabelea, D.; Dagogo-Jack, S.; Hamman, R. F.; Kahn, S. E.; Mather, Kieren; Knowler, W. C.

In: Diabetic Medicine, 2017.

Research output: Contribution to journalArticle

Perreault, L, Pan, Q, Aroda, VR, Barrett-Connor, E, Dabelea, D, Dagogo-Jack, S, Hamman, RF, Kahn, SE, Mather, K & Knowler, WC 2017, 'Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS)', Diabetic Medicine. https://doi.org/10.1111/dme.13453
Perreault, L. ; Pan, Q. ; Aroda, V. R. ; Barrett-Connor, E. ; Dabelea, D. ; Dagogo-Jack, S. ; Hamman, R. F. ; Kahn, S. E. ; Mather, Kieren ; Knowler, W. C. / Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). In: Diabetic Medicine. 2017.
@article{f04a672e5637435bb9a2756e27cea247,
title = "Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS)",
abstract = "Aim: Approximately half of the participants in the Diabetes Prevention Outcomes Study (DPPOS) had diabetes after 15 years of follow-up, whereas nearly all the others remained with pre-diabetes. We examined whether formerly unexplored factors in the DPPOS coexisted with known risk factors that posed additional risk for, or protection from, diabetes as well as microvascular disease. Methods: Cox proportional hazard models were used to examine predictors of diabetes. Sequential modelling procedures considered known and formerly unexplored factors. We also constructed models to determine whether the same unexplored factors that associated with progression to diabetes also predicted the prevalence of microvascular disease. Hazard ratios (HR) are per standard deviation change in the variable. Results: In models adjusted for demographics and known diabetes risk factors, two formerly unknown factors were associated with risk for both diabetes and microvascular disease: number of medications taken (HR = 1.07, 95{\%} confidence intervals (95{\%} CI) 1.03 to 1.12 for diabetes; odds ratio (OR) = 1.10, 95{\%} CI 1.04 to 1.16 for microvascular disease) and variability in HbA1c (HR = 1.02, 95{\%} CI 1.01 to 1.03 for diabetes; OR = 1.06, 95{\%} CI 1.04 to 1.09 for microvascular disease per sd). Total comorbidities increased risk for diabetes (HR = 1.10, 95{\%} CI 1.04 to 1.16), whereas higher systolic (OR = 1.22, 95{\%} CI 1.13 to 1.31) and diastolic (OR = 1.14, 95{\%} CI 1.05 to 1.22) blood pressure, as well as the use of anti-hypertensives (OR = 1.41, 95{\%} CI 1.23 to 1.62), increased risk of microvascular disease. Conclusions: Several formerly unexplored factors in the DPPOS predicted additional risk for diabetes and/or microvascular disease - particularly hypertension and the use of anti-hypertensive medications - helping to explain some of the residual disease risk in participants of the DPPOS.",
author = "L. Perreault and Q. Pan and Aroda, {V. R.} and E. Barrett-Connor and D. Dabelea and S. Dagogo-Jack and Hamman, {R. F.} and Kahn, {S. E.} and Kieren Mather and Knowler, {W. C.}",
year = "2017",
doi = "10.1111/dme.13453",
language = "English (US)",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS)

AU - Perreault, L.

AU - Pan, Q.

AU - Aroda, V. R.

AU - Barrett-Connor, E.

AU - Dabelea, D.

AU - Dagogo-Jack, S.

AU - Hamman, R. F.

AU - Kahn, S. E.

AU - Mather, Kieren

AU - Knowler, W. C.

PY - 2017

Y1 - 2017

N2 - Aim: Approximately half of the participants in the Diabetes Prevention Outcomes Study (DPPOS) had diabetes after 15 years of follow-up, whereas nearly all the others remained with pre-diabetes. We examined whether formerly unexplored factors in the DPPOS coexisted with known risk factors that posed additional risk for, or protection from, diabetes as well as microvascular disease. Methods: Cox proportional hazard models were used to examine predictors of diabetes. Sequential modelling procedures considered known and formerly unexplored factors. We also constructed models to determine whether the same unexplored factors that associated with progression to diabetes also predicted the prevalence of microvascular disease. Hazard ratios (HR) are per standard deviation change in the variable. Results: In models adjusted for demographics and known diabetes risk factors, two formerly unknown factors were associated with risk for both diabetes and microvascular disease: number of medications taken (HR = 1.07, 95% confidence intervals (95% CI) 1.03 to 1.12 for diabetes; odds ratio (OR) = 1.10, 95% CI 1.04 to 1.16 for microvascular disease) and variability in HbA1c (HR = 1.02, 95% CI 1.01 to 1.03 for diabetes; OR = 1.06, 95% CI 1.04 to 1.09 for microvascular disease per sd). Total comorbidities increased risk for diabetes (HR = 1.10, 95% CI 1.04 to 1.16), whereas higher systolic (OR = 1.22, 95% CI 1.13 to 1.31) and diastolic (OR = 1.14, 95% CI 1.05 to 1.22) blood pressure, as well as the use of anti-hypertensives (OR = 1.41, 95% CI 1.23 to 1.62), increased risk of microvascular disease. Conclusions: Several formerly unexplored factors in the DPPOS predicted additional risk for diabetes and/or microvascular disease - particularly hypertension and the use of anti-hypertensive medications - helping to explain some of the residual disease risk in participants of the DPPOS.

AB - Aim: Approximately half of the participants in the Diabetes Prevention Outcomes Study (DPPOS) had diabetes after 15 years of follow-up, whereas nearly all the others remained with pre-diabetes. We examined whether formerly unexplored factors in the DPPOS coexisted with known risk factors that posed additional risk for, or protection from, diabetes as well as microvascular disease. Methods: Cox proportional hazard models were used to examine predictors of diabetes. Sequential modelling procedures considered known and formerly unexplored factors. We also constructed models to determine whether the same unexplored factors that associated with progression to diabetes also predicted the prevalence of microvascular disease. Hazard ratios (HR) are per standard deviation change in the variable. Results: In models adjusted for demographics and known diabetes risk factors, two formerly unknown factors were associated with risk for both diabetes and microvascular disease: number of medications taken (HR = 1.07, 95% confidence intervals (95% CI) 1.03 to 1.12 for diabetes; odds ratio (OR) = 1.10, 95% CI 1.04 to 1.16 for microvascular disease) and variability in HbA1c (HR = 1.02, 95% CI 1.01 to 1.03 for diabetes; OR = 1.06, 95% CI 1.04 to 1.09 for microvascular disease per sd). Total comorbidities increased risk for diabetes (HR = 1.10, 95% CI 1.04 to 1.16), whereas higher systolic (OR = 1.22, 95% CI 1.13 to 1.31) and diastolic (OR = 1.14, 95% CI 1.05 to 1.22) blood pressure, as well as the use of anti-hypertensives (OR = 1.41, 95% CI 1.23 to 1.62), increased risk of microvascular disease. Conclusions: Several formerly unexplored factors in the DPPOS predicted additional risk for diabetes and/or microvascular disease - particularly hypertension and the use of anti-hypertensive medications - helping to explain some of the residual disease risk in participants of the DPPOS.

UR - http://www.scopus.com/inward/record.url?scp=85030030233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030030233&partnerID=8YFLogxK

U2 - 10.1111/dme.13453

DO - 10.1111/dme.13453

M3 - Article

C2 - 28833481

AN - SCOPUS:85030030233

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

ER -